Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698331 | Clinical Oncology | 2017 | 9 Pages |
Abstract
A hypofractionated radiotherapy schedule, 60Â Gy in 20 fractions with intra-prostatic boost dose of 68Â Gy, can be achieved without exceeding dose constraints for organs at risk. Hypofractionated dose-painting escalated radiotherapy has an acceptable safety profile. The same planning protocol was used in a phase II single-arm trial (BIOPROP20: ClinicalTrials.gov identifier NCT02125175) and will further be used in a large phase III randomised trial (PIVOTALboost): patients will be randomised standard radiotherapy (60Â Gy in 20 fractions) with or without lymph node radiotherapy versus dose-painting radiotherapy with or without lymph node radiotherapy; the trial will be opened for recruitment in summer 2017.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
E. Onjukka, J. Uzan, C. Baker, L. Howard, A. Nahum, I. Syndikus,